$ALLO
Allogene Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000173728724000056 Filed on August 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.33M $16.09M
YoY Change -4.15% -13.16%
% of Gross Profit
Research & Development $44.71M $50.36M
YoY Change -2.75% -18.83%
% of Gross Profit
Depreciation & Amortization $3.207M $3.644M
YoY Change -10.17% 0.03%
% of Gross Profit
Operating Expenses $71.77M $71.43M
YoY Change 13.89% -11.33%
Operating Profit -$71.77M -$71.43M
YoY Change 13.97% -11.29%
Interest Expense $5.481M $4.988M
YoY Change -11.74% 32.03%
% of Operating Profit
Other Income/Expense, Net $5.481M $5.073M
YoY Change 230.18% -506.16%
Pretax Income -$66.29M -$66.36M
YoY Change 8.11% -14.91%
Income Tax
% Of Pretax Income
Net Earnings -$66.29M -$66.36M
YoY Change 8.12% -14.91%
Net Earnings / Revenue
Basic Earnings Per Share -$0.32 -$0.35
Diluted Earnings Per Share -$0.32 -$0.35
COMMON SHARES
Basic Shares Outstanding 209.1M shares 170.9M shares
Diluted Shares Outstanding 209.2M shares 190.0M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $291.6M $444.6M
YoY Change -37.37% -9.62%
Cash & Equivalents $51.24M $170.7M
Short-Term Investments $240.3M $274.0M
Other Short-Term Assets $12.85M $12.50M
YoY Change 62.67% 23.25%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $304.4M $457.1M
YoY Change -35.7% -8.96%
LONG-TERM ASSETS
Property, Plant & Equipment $88.99M $92.08M
YoY Change -13.46% -50.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $111.8M $1.134M
YoY Change 198.19% -98.19%
Other Assets $4.970M $6.439M
YoY Change -48.1% -67.27%
Total Long-Term Assets $284.7M $189.8M
YoY Change 19.19% -29.42%
TOTAL ASSETS
Total Short-Term Assets $304.4M $457.1M
Total Long-Term Assets $284.7M $189.8M
Total Assets $589.1M $646.9M
YoY Change -17.3% -16.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.506M $12.94M
YoY Change -11.27% 26.46%
Accrued Expenses $27.07M $24.37M
YoY Change -13.25% -44.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $32.57M $37.31M
YoY Change -13.46% -31.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.666M $7.551M
YoY Change 415.88% -91.91%
Total Long-Term Liabilities $7.666M $7.551M
YoY Change 415.88% -91.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.57M $37.31M
Total Long-Term Liabilities $7.666M $7.551M
Total Liabilities $125.4M $131.8M
YoY Change -2.98% -10.95%
SHAREHOLDERS EQUITY
Retained Earnings -$1.760B -$1.694B
YoY Change 17.33% 20.97%
Common Stock $2.223B $2.209B
YoY Change 7.96% 8.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $463.7M $515.0M
YoY Change
Total Liabilities & Shareholders Equity $589.1M $646.9M
YoY Change -17.3% -16.1%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$66.29M -$66.36M
YoY Change 8.12% -14.91%
Depreciation, Depletion And Amortization $3.207M $3.644M
YoY Change -10.17% 0.03%
Cash From Operating Activities -$44.12M -$63.59M
YoY Change -20.56% 2.8%
INVESTING ACTIVITIES
Capital Expenditures $429.0K $0.00
YoY Change 2045.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$75.56M $74.61M
YoY Change 120.56% 327.63%
Cash From Investing Activities -$75.99M $74.61M
YoY Change 121.74% 334.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 679.0K 108.6M
YoY Change -84.14% 21.31%
NET CHANGE
Cash From Operating Activities -44.12M -63.59M
Cash From Investing Activities -75.99M 74.61M
Cash From Financing Activities 679.0K 108.6M
Net Change In Cash -119.4M 119.6M
YoY Change 39.65% 166.87%
FREE CASH FLOW
Cash From Operating Activities -$44.12M -$63.59M
Capital Expenditures $429.0K $0.00
Free Cash Flow -$44.54M -$63.59M
YoY Change -19.81% 2.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
168642238 shares
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
10292000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
10292000 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6439000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6604000 usd
CY2024Q2 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
1134000 usd
CY2023Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
3645000 usd
CY2024Q2 us-gaap Assets
Assets
646883000 usd
CY2023Q4 us-gaap Assets
Assets
642837000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
12936000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5897000 usd
CY2024Q2 allo Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
24369000 usd
CY2023Q4 allo Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
31182000 usd
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
168642238 shares
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
71431000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
80562000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-71431000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-80540000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
85000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2470000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5073000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1308000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-66358000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-79232000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
147000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2083000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66211000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-77149000 usd
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
190026638 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
190026638 shares
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
179577500 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
179577500 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1323000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50355000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62038000 usd
CY2024Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://allogene.com/20240630#AccruedAndOtherLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://allogene.com/20240630#AccruedAndOtherLiabilitiesCurrent
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
58385000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
63703000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92080000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
99478000 usd
CY2024Q2 us-gaap Escrow Deposit
EscrowDeposit
21429000 usd
CY2023Q4 us-gaap Escrow Deposit
EscrowDeposit
0 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
37305000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
37079000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
86989000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
88346000 usd
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7551000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5179000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
131845000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
130604000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
209049485 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
209049485 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
209000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
169000 usd
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2209200000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2075252000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1693591000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1562233000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-780000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-955000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
515038000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
512233000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
646883000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
642837000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16087000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18524000 usd
CY2024Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
4989000 usd
CY2023Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4988000 usd
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3778000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
10421000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
5837000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-844000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5405000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9577000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
432000 usd
us-gaap Net Income Loss
NetIncomeLoss
-131358000 usd
us-gaap Net Income Loss
NetIncomeLoss
-179200000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
175000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
6075000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-131183000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-173125000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.73
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146795826 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146795826 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
145685993 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
145685993 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
512233000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
794000 usd
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
532000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11924000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
856000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-65000000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
28000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
461367000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
19000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13559000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-66358000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
147000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
515038000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
666882000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0 usd
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
603000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18770000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1731000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-99968000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
3992000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
592010000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1606000 usd
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
432000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16594000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-79232000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2083000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
621411000 usd
us-gaap Profit Loss
ProfitLoss
-131358000 usd
us-gaap Profit Loss
ProfitLoss
-179200000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
25483000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
35364000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7199000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7150000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
4998000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
566000 usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
4989000 usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
allo Operating Lease Noncash Expense
OperatingLeaseNoncashExpense
-151000 usd
allo Operating Lease Noncash Expense
OperatingLeaseNoncashExpense
357000 usd
allo Noncash Collaboration Revenue
NoncashCollaborationRevenue
14000 usd
allo Noncash Collaboration Revenue
NoncashCollaborationRevenue
34000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-554000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-5370000 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
21429000 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1953000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1365000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-2122000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
55000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6690000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3233000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6670000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5607000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
49000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-621000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-119487000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-128496000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
5623000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
220493000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
296309000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
123739000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
170514000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
96746000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
130095000 usd
allo Proceeds From Grant Awards
ProceedsFromGrantAwards
2280000 usd
allo Proceeds From Grant Awards
ProceedsFromGrantAwards
0 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
813000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1606000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
856000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1731000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
110253000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
91255000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
87512000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
92854000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93447000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72196000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
180959000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165050000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2409000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
allo Noncash Or Part Noncash Deferred Revenue And Other Long Term Liabilities
NoncashOrPartNoncashDeferredRevenueAndOtherLongTermLiabilities
3079000 usd
allo Noncash Or Part Noncash Deferred Revenue And Other Long Term Liabilities
NoncashOrPartNoncashDeferredRevenueAndOtherLongTermLiabilities
3122000 usd
us-gaap Payments For Leasing Costs Commissions And Tenant Improvements
PaymentsForLeasingCostsCommissionsAndTenantImprovements
6173000 usd
us-gaap Payments For Leasing Costs Commissions And Tenant Improvements
PaymentsForLeasingCostsCommissionsAndTenantImprovements
5989000 usd
us-gaap Nature Of Operations
NatureOfOperations
Description of Business<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November 30, 2017 in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. The Company is developing a pipeline of “off-the-shelf” T cell product candidates that are designed to target and kill cancer cells in patients or eliminate pathogenic autoreactive cells in patients with autoimmune disorders. The Company’s engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient’s use, as in the case of autologous T cells. The Company believes this key difference will enable it to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registered Offering</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 13, 2024, the Company entered into (i) an underwriting agreement (Underwriting Agreement) with Goldman Sachs &amp; Co. LLC (Underwriter) and (ii) a Securities Purchase Agreement (Securities Purchase Agreement)    with certain members of the Company’s Board of Directors and executive officers or their respective affiliates (Purchasers), pursuant to which the Company sold and issued to the Underwriter and the Purchasers an aggregate of 37,931,035 shares of common stock of the Company at a purchase price of $2.90 per share, in a registered offering transaction (Registered Offering) for aggregate gross proceeds of $110.0 million, before deducting the underwriting discount and commissions and estimated offering expenses payable by the Company. The Registered Offering closed on May 16, 2024. The aggregate fee payable by the Company to the Underwriter was $4.7 million, plus the reimbursement of certain expenses. The Purchasers purchased an aggregate of 1,034,484 shares of common stock of the Company in the Registered Offering.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Need for Additional Capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company’s ultimate success depends on the outcome of its research and development activities as well as the ability to commercialize the Company's product candidates.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company had cash and cash equivalents and investments of $444.6 million as of June 30, 2024. Since inception through June 30, 2024, the Company has incurred cumulative net losses of $1,693.6 million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</span></div>The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for at least the next 12 months from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC).
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
444600000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1693600000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of investments, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.</span></div>
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
435840000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
9000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
345000 usd
CY2024Q2 allo Cash Equivalents And Short Term Investments
CashEquivalentsAndShortTermInvestments
435504000 usd
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
161543000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
273961000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0 usd
CY2024Q2 allo Cash Equivalents And Short Term Investments
CashEquivalentsAndShortTermInvestments
435504000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
444589000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
245000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
756000 usd
CY2023Q4 allo Cash Equivalents And Short Term Investments
CashEquivalentsAndShortTermInvestments
444078000 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
78536000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
365542000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0 usd
CY2023Q4 allo Cash Equivalents And Short Term Investments
CashEquivalentsAndShortTermInvestments
444078000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P1Y
CY2024Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
1000000.0 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
17700000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
48400000 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
2000000.0 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
1700000 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
148442000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
150562000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
56362000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
51084000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92080000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
99478000 usd
CY2018Q3 allo Area Of New Office Building
AreaOfNewOfficeBuilding
68000 sqft
CY2018Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P127M
CY2018Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P7Y
CY2020Q4 us-gaap Tenant Improvements
TenantImprovements
5000000.0 usd
CY2021Q4 allo Additional Area Of New Office Building
AdditionalAreaOfNewOfficeBuilding
47566 sqft
CY2018Q4 allo Area Of New Office Building
AreaOfNewOfficeBuilding
14943 sqft
CY2018Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P124M
CY2018Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P7Y
CY2018Q4 allo Tenant Improvement Allowance
TenantImprovementAllowance
800000 usd
CY2023Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
6000000 usd
CY2024Q2 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
6000000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7221000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6775000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
86989000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
88346000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
94210000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
95121000 usd
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
3011000 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
3175000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
6031000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
6356000 usd
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
508000 usd
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
672000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
1375000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
1363000 usd
CY2024Q2 us-gaap Lease Cost
LeaseCost
3519000 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
3847000 usd
us-gaap Lease Cost
LeaseCost
7406000 usd
us-gaap Lease Cost
LeaseCost
7719000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
6200000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
6382000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
12920000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
13163000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
13612000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
14076000 usd
CY2024Q2 allo Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
65386000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
125539000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
31329000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
94210000 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0624
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y6M29D
CY2020Q3 us-gaap Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
P20Y
CY2020Q3 allo Lessee Finance Lease Payment Upon Contract Termination
LesseeFinanceLeasePaymentUponContractTermination
4300000 usd
CY2024Q2 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
700000 usd
allo Number Of Shares As Percentage Of Common Shares Outstanding
NumberOfSharesAsPercentageOfCommonSharesOutstanding
0.05
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9817735 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
5200000 usd
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13600000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25500000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16600000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35400000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38233827 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
36609115 shares

Files In Submission

Name View Source Status
0001737287-24-000056-index-headers.html Edgar Link pending
0001737287-24-000056-index.html Edgar Link pending
0001737287-24-000056.txt Edgar Link pending
0001737287-24-000056-xbrl.zip Edgar Link pending
allo-20240630.htm Edgar Link pending
allo-20240630.xsd Edgar Link pending
allo-20240630xex101.htm Edgar Link pending
allo-20240630xex102.htm Edgar Link pending
allo-20240630xex103.htm Edgar Link pending
allo-20240630xex104.htm Edgar Link pending
allo-20240630xex106.htm Edgar Link pending
allo-20240630xex107.htm Edgar Link pending
allo-20240630xex311.htm Edgar Link pending
allo-20240630xex312.htm Edgar Link pending
allo-20240630xex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
allo-20240630_cal.xml Edgar Link unprocessable
allo-20240630_def.xml Edgar Link unprocessable
allo-20240630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
allo-20240630_pre.xml Edgar Link unprocessable
allo-20240630_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending